ADX 10061
Alternative Names: ADX-10061; CEE 310; CEE-03-310; NNC 010687; NNC 687Latest Information Update: 03 Oct 2007
At a glance
- Originator Novo Nordisk
- Developer Addex Pharmaceuticals
- Class Antipsychotics; Benzazepines; Sleep disorder therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Dopamine D1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Schizophrenia; Sleep disorders; Smoking withdrawal; Substance-related disorders
Most Recent Events
- 03 Oct 2007 Discontinued - Phase-II for Smoking withdrawal in USA (PO)
- 03 Aug 2007 Discontinued - Phase-II for Sleep disorders in USA (PO)
- 03 Aug 2007 Discontinued - Phase-II for Substance-related disorders in USA (PO)